Mysoline Prices — US Pharmacy Cost vs Canada — Save Up to 66% in the US

Our most recent US pharmacy data shows a low of roughly $5.09 for Primidone with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.

Yes — Cost Plus Drugs lists Primidone at roughly $0.034 per unit, a published price with no membership card or coupon involved. See the three-price comparison above for how that stacks up against discount-card pharmacies.

We found Canadian pricing for Primidone starting near $0.100 per tablet in USD terms. That's before any shipping charge, which the table above breaks out separately.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. In this case, our data shows the US price is actually the lower of the two once a program like Cost Plus Drugs is factored in — the assumption that Canada is always cheaper doesn't hold for every drug.

The out-of-pocket cost for Mysoline with insurance depends entirely on your specific plan's formulary, deductible, and copay structure. You should contact your insurance provider directly to confirm coverage details. If your plan does not cover brand-name Mysoline or requires a high copay, your doctor can often prescribe the generic primidone, which is typically covered at a lower tier. For medications not covered by insurance, including Medicare or Medicaid, patients can explore pharmacy savings cards, manufacturer assistance programs, or compare cash prices at different pharmacies to find the best available rate.

Yes, the generic name for brand-name Mysoline is primidone. Generic primidone contains the same active pharmaceutical ingredient and is approved as a therapeutic equivalent, but it is usually available at a substantially lower price than the brand. While the brand medication may cost hundreds of dollars, the generic can often be obtained for a fraction of that cost, making it a cost-effective option for long-term management of seizure disorders.